aTYR PHARMA INC Gain (Loss) on Extinguishment of Debt
aTYR PHARMA INC (ATYR) reported Gain (Loss) on Extinguishment of Debt of -$29.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2019-03-26
- aTYR PHARMA INC gain (loss) on extinguishment of debt for fiscal 2016 was -$29.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|
| 2016-12-31 | -$29.00K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |